Industry Optimistic About Second CDS Draft Guidance; FDA Releases More Final Software Guidances
Executive Summary
After strong pushback to a clinical decision support (CDS) software draft guidance, it seems the US agency has decided to heed industry concerns to take a more risk-based approach by issuing another draft of the guidance. Industry sources are applauding the FDA's move, saying it gives them another opportunity to fine-tune the regulations, which could mean fewer CDS manufacturers would be regulated by the agency.
You may also be interested in...
OTS Software Guidance Update Underscores Industry Advancements
The Off-the-Shelf Software Guidance updates highlight industry advancements.
Petition Argues FDA’s CDS Software Guidance Violates The Law
CDS Coalition legal counsel Bradley Thompson broke down the citizen petition calling for the US FDA to rescind the Clinical Decision Software guidance based on legal and procedural violations.
Expert: New Guidance May Demand Clinical Decision Support Software Re-Evaluation
Businesses should reevaluate the classification of their clinical decision software based on a new FDA guidance, Kyle Faget of Foley & Lardner LLP tells Medtech Insight.